Navigation Links
Record Year for CEM's Peptide Synthesis Business
Date:7/27/2011

MATTHEWS, N.C., July 27, 2011 /PRNewswire/ -- CEM Corporation, a leading global provider of microwave laboratory instrumentation, continues to see strong success with its microwave peptide synthesis products. In FY2011 year-to-date, the company has seen significant growth versus the prior year in its automated peptide synthesizer instrument sales and is on pace to easily sell a record number of systems. Additionally, CEM's products were well received at the recent American Peptide Symposium, which was held June 25-30, 2011 in San Diego, CA, including its new semi-automated microwave peptide synthesizer, the Discover® SPS Plus.

(Logo: http://photos.prnewswire.com/prnh/20090622/CL35336LOGO-b)

"We are very pleased with our successful results this year," said Michael J. Collins, president and CEO of CEM Corporation. "They continue to demonstrate that CEM is the leader in peptide synthesis. Our technology is now broadly accepted and has been transformational in enhancing peptide synthesis."

CEM has been awarded multiple patents related to the use of microwave energy for peptide synthesis(1). CEM's patented process uses microwave energy to enhance both the deprotection and coupling steps in manual and automated peptide synthesis. This means that other microwave peptide synthesizers (manual or automated) are limited to applying microwave energy only in the deprotection or coupling step in a single vessel.

"An average length peptide contains many deprotection and coupling steps. As incomplete reactions are routinely observed in both steps, it is a significant disadvantage to use microwave energy for only one of the two reactions at each cycle," explained Collins. "Our patented process is faster and results in higher purity peptides, giving CEM a long-term advantage in the field."

Access to the patented process is included with the purchase of any of CEM's manual, semi-automated, or fully automated peptide synthesizers. This technology is not available with other microwave peptide synthesizers.

CEM designed, developed, and introduced the world's first microwave peptide synthesizer to the scientific community in 2003. Since that time, CEM has expanded its portfolio to include manual, semi-automated, fully automated (single channel), and fully automated (12-channel) systems. All of CEM's peptide synthesizers can operate under conventional conditions, microwave conditions, or a combination of both. Both fully automated systems can be equipped with an optional UV monitoring system. Additionally, the manual and semi-automated systems can be upgraded to either of the fully automated versions.

Each one of CEM's peptide synthesizers utilizes in-situ fiber optic temperature monitoring during heating. In-situ temperature monitoring helps avoid temperature overshoots from use of external IR monitoring, which can lead to significant side reactions. In 2007, researchers at CEM showed in a major publication that precise temperature control limits major side reactions such as racemization and aspartimide formation(2).   CEM's methods are now routinely used in hundreds of laboratories worldwide.

(1) Including among others US7,563,865; US7,582,728; US7,393,920, EP1491552. Additional International Patents filed and pending.

(2) Palasek S., Cox Z., Collins J., J. Pept. Sci.13,143-148, 2007.

CEM Corporation, a private company based in Matthews, North Carolina, is the leading global company specializing in scientific solutions for critical laboratory applications. The Company has subsidiaries in the United Kingdom, Germany, Italy, France, and Japan, as well as a global network of distributors. CEM designs and manufactures systems for bioscience applications, life sciences, analytical laboratories and processing plants worldwide. The Company's products are used in many industries including pharmaceutical, biotech, chemical and food processing, as well as academic research.


'/>"/>
SOURCE CEM Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sinovac Reports Record Second Quarter 2008 Unaudited Financial Results
2. Huifeng Bio-Pharmaceutical (HFGB) Reports over $5 Million in Gross Sales; Record Results for the First Half of 2008
3. China Kangtai Cactus Biotech Announces Record Second Quarter Results
4. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
5. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results
6. Concentric Named Professional Agency of Record for Discovery Labs SURFAXIN(R)
7. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
8. Biotel Announces Record Revenues and Earnings for Fiscal 2008
9. Octapharma USA Retains Yankee Public Relations as its Agency of Record
10. Abaxis Reports Record Revenues and Operating Income for the Second Quarter of Fiscal 2009
11. Womens Surgery Recorded for the First Time on 4K Digital Cinema is Presented at the AAGL Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... (TDR) procedures can be safely completed in an ambulatory surgery center (ASC) with ... (ACDF) procedures and previous two-year TDR studies. , Jake Lubinski, president of ...
(Date:2/24/2017)... , Feb. 24, 2017 Symic Bio, a ... a new category of therapeutics, announced today the completion ... in peripheral artery disease. The trial will evaluate the ... therapeutic, in the reduction of restenosis following angioplasty. ... development milestone for SB-030," said Nathan Bachtell , ...
(Date:2/24/2017)... Corporation (NASDAQ: VWR), the leading global independent provider of product ... its financial results for the fourth quarter and full year ... 4Q16 record quarterly net sales of $1.13 billion, up ... 4Q16 EMEA-APAC segment net sales increased ... net sales increased 2.5%, or down 0.9% on an organic ...
(Date:2/23/2017)... - The Fight Against Cancer Innovation Trust (FACIT) and ... to report that Fusion Pharmaceuticals Inc. (Fusion) has closed ... Innovation – JJDC, Inc. (JJDC) as the lead investor. ... Partners, and Genesys Capital, as well as founding investor ... ...
Breaking Biology Technology:
(Date:2/2/2017)... , Feb. 2, 2017  EyeLock LLC, a market ... new white paper " What You Should Know About ... of ensuring user authenticity is a growing concern. In ... of users. However, traditional authentication schemes such as username/password ... Biometric authentication offers an elegant solution to the ...
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... fastest growing genetic information companies, today announced that it ... results and provide 2017 guidance on Monday, February 13, ... call that day at 4:45 p.m. Eastern / 1:45 ... management team will briefly review financial results, guidance, and ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
Breaking Biology News(10 mins):